Float Short %

24.51

Margin Of Safety %

Put/Call OI Ratio

0.22

EPS Next Q Diff

EPS Last/This Y

0.19

EPS This/Next Y

0.14

Price

2.26

Target Price

10.2

Analyst Recom

Performance Q

-12.06

Relative Volume

Beta

-0.11

Ticker: IBRX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	IBRX	2.15	0.21	2.12	286212
2025-11-11	IBRX	2.13	0.21	0.92	287028
2025-11-12	IBRX	2.06	0.22	1.29	286775
2025-11-13	IBRX	2	0.22	0.33	287115
2025-11-14	IBRX	2.07	0.21	0.03	287272
2025-11-17	IBRX	2.03	0.21	1.50	291753
2025-11-18	IBRX	2.1	0.21	0.11	293545
2025-11-19	IBRX	2.14	0.21	0.03	298472
2025-11-20	IBRX	2.03	0.21	0.17	301447
2025-11-21	IBRX	2.08	0.20	0.54	294363
2025-11-24	IBRX	2.12	0.22	0.04	263955
2025-11-25	IBRX	2.08	0.21	1.22	266272
2025-11-26	IBRX	2.12	0.21	0.13	266776
2025-12-01	IBRX	2.29	0.21	0.09	272873
2025-12-02	IBRX	2.09	0.21	0.72	275848
2025-12-03	IBRX	2.19	0.22	0.10	281819
2025-12-04	IBRX	2.3	0.22	0.06	283995
2025-12-05	IBRX	2.29	0.22	0.26	285735
2025-12-08	IBRX	2.25	0.22	0.10	286576
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	IBRX	2.16	16.7	48.5	-0.44
2025-11-11	IBRX	2.14	-37.5	52.7	-0.44
2025-11-12	IBRX	2.06	-37.5	58.4	-0.44
2025-11-13	IBRX	2.00	-37.5	56.5	-0.44
2025-11-14	IBRX	2.07	-37.5	45.5	-0.44
2025-11-17	IBRX	2.03	-37.5	55.6	-0.44
2025-11-18	IBRX	2.10	-20.8	45.5	-0.40
2025-11-19	IBRX	2.14	-20.8	48.2	-0.40
2025-11-20	IBRX	2.03	-20.8	60.8	-0.40
2025-11-21	IBRX	2.09	-20.8	46.3	-0.40
2025-11-24	IBRX	2.15	-20.8	45.6	-0.40
2025-11-25	IBRX	2.08	-20.8	57.1	-0.40
2025-11-26	IBRX	2.12	-20.8	47.7	-0.40
2025-12-01	IBRX	2.29	-20.8	56.6	-0.40
2025-12-02	IBRX	2.09	-20.8	67.4	-0.40
2025-12-03	IBRX	2.20	-20.8	42.2	-0.40
2025-12-04	IBRX	2.29	-20.8	44.4	-0.40
2025-12-05	IBRX	2.29	-20.8	52.2	-0.40
2025-12-08	IBRX	2.26	-20.8	-	-0.40
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	IBRX	0.00	16.91	23.92
2025-11-11	IBRX	0.00	16.91	23.92
2025-11-12	IBRX	0.00	16.91	24.32
2025-11-13	IBRX	0.00	16.91	24.32
2025-11-14	IBRX	0.00	16.91	24.32
2025-11-17	IBRX	0.00	16.25	24.32
2025-11-18	IBRX	0.00	16.25	24.32
2025-11-19	IBRX	0.00	16.25	24.32
2025-11-20	IBRX	0.00	16.25	24.32
2025-11-21	IBRX	0.00	16.25	24.32
2025-11-24	IBRX	0.00	6.11	24.32
2025-11-25	IBRX	0.00	6.11	24.32
2025-11-26	IBRX	0.00	6.11	26.73
2025-12-01	IBRX	0.00	6.10	24.51
2025-12-02	IBRX	0.00	6.10	24.51
2025-12-03	IBRX	0.00	6.10	24.51
2025-12-04	IBRX	0.00	6.10	24.51
2025-12-05	IBRX	0.00	6.10	24.51
2025-12-08	IBRX	0.00	6.13	24.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

Institutional Transactions

6.13

Beta

-0.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

94.5

Max Drawdown 5-Year %

Target Price

10.2

P/E

Forward P/E

PEG

P/S

26.96

P/B

P/Free Cash Flow

EPS

-0.42

Average EPS Est. Cur. Y

-0.4

EPS Next Y. (Est.)

-0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-422.28

Relative Volume

Return on Equity vs Sector %

39.6

Return on Equity vs Industry %

54.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

ImmunityBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 673

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today

news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance

stock history IBRX – ImmunityBio, Inc. invest stock market

stock prices IBRX premarket after hours

ticker IBRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IBRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y